Cagrilintide: the amylin arm, and why it is studied alongside semaglutide

A once-weekly analogue of amylin — the pancreatic hormone released alongside insulin at every meal. It is interesting mostly because it works through a pathway the GLP-1 drugs do not touch, which is why it is being developed as a partner rather than a rival.

Amylin is the other beta-cell hormone

Established clinical use Beta cells co-secrete two hormones in response to a meal: insulin, and amylin. Amylin's job is to slow the arrival of nutrients and signal that a meal has happened. It delays gastric emptying, suppresses postprandial glucagon, and acts on receptors in the area postrema — a brainstem region outside the blood-brain barrier — to promote satiety. Those receptors are not GLP-1 receptors, and that is the entire strategic point of the compound.

Native amylin is unusable as a drug because it aggregates into insoluble fibrils. Pramlintide, an approved analogue used with insulin in diabetes, solved the aggregation problem but has a half-life measured in minutes and requires dosing at every meal. Cagrilintide is a long-acting analogue with a fatty-acid modification of the kind that made semaglutide weekly; the app models its half-life at about seven and a half days and flags it as an estimate.

Why the trials pair it with semaglutide

Established clinical use Two satiety pathways that act through different receptors should combine, and that is what the development programme set out to test. The fixed-dose combination of cagrilintide and semaglutide has been through phase III in adults with obesity, reporting mean weight reduction of roughly 22-23% at 68 weeks. That is above semaglutide's own figure in a comparable trial and in the region of the highest results reported for any approved agent.

Cagrilintide has also been studied on its own, where the effect is real but considerably smaller than the combination's. The reasonable summary is that this is a compound designed to be additive rather than a standalone therapy, and the evidence supports reading it that way.

Off-label or community practice The tolerability question is the interesting one for a combination. Two agents that both slow gastric emptying and both act on nausea pathways could plausibly compound gastrointestinal effects rather than dividing them, and the trial programme is where that gets characterised. Reported effects follow the class pattern — nausea and gastrointestinal upset, worst during titration.

It is not approved, and that has practical consequences

Cagrilintide is not approved anywhere, alone or in combination. The dosing rows above are trial amounts reproduced so the numbers people cite can be seen in context; they were administered inside trials with monitoring and stopping rules that do not exist outside one. This page does not tell anyone to take an amount, and no vendor, pharmacy or testing service appears anywhere on this site.

Anything obtainable now is a research-supply preparation whose identity, purity and concentration rest entirely with whoever produced it, and for a peptide whose native form is prone to aggregation, formulation is not a trivial detail. A preparation that has aggregated is not the same molecule in solution, and there is no way to tell by looking.

As with the rest of the class, the muscle-composition question applies and scales with the size of the deficit, and the standard response — resistance training and adequate protein — is inference rather than a tested combination. Anyone considering this should be weighing it against approved agents that have completed the process, with a clinician who can make that comparison.

How long one dose lasts

Try other intervals on the half-life and steady-state calculator, which runs the same function against whatever cadence you type.

The dosing rows the app records

Animal-only or theoretical Reproduced from the app’s reference so you can see what it holds, not as a recommendation. Which row applies to a particular person, if any, is a clinical decision this page does not make — and rows describing supraphysiological or post-cycle use are filtered out before this table is built, so what you see here is a subset.

What the app monitors alongside it

The panel below is the app’s own monitoring note for Cagrilintide, verbatim. The analytes in it that have a page here are linked; those pages cover what each one measures, which assay produced it and how to read a trend.

• Hematocrit on testosterone therapy
• HbA1c and fasting glucose

Drawbacks and risks the app records

From the app's own entry. The availability item is the one that governs everything else: there is no approved product, so there is no product whose contents anyone has verified.

• Not FDA approved
• Nausea and GI effects similar to GLP-1 class
• Phase III trials ongoing
• Not yet commercially available
• Muscle preservation still requires testosterone support
• Long-term safety data accumulating

Interaction rules that name Cagrilintide

From the app’s interaction data, filtered so no rule naming a compound this site does not publish appears. Not exhaustive, and not a safety clearance: a combination that is not listed is one nobody has documented here, which is not the same as one that is fine. The combination checker has the rest.

Questions people actually ask

How is amylin different from GLP-1?

Different hormone, different receptors, different origin — amylin comes from the pancreatic beta cell alongside insulin, GLP-1 from the gut. Both slow gastric emptying and promote satiety, but through separate signalling, which is why combining them is expected to add rather than overlap.

Is pramlintide the same idea?

Same class, and it is the approved proof that an amylin analogue can work in people. It is short-acting and dosed with meals, which is a substantial practical difference. Cagrilintide is the attempt to make the mechanism weekly.

Can it be used with a GLP-1 drug?

That is precisely what the phase III programme tested, as a fixed-dose combination product. Assembling an equivalent from separate unapproved preparations is not the same thing as the combination that was studied, and this page will not describe how to do it.

How long does it stay in the system?

The app models about seven and a half days and flags the figure as an estimate. At that half-life, a weekly schedule accumulates for around five weeks before it plateaus, and clearance after stopping takes a similar time.

Where the load-bearing numbers come from

Named rather than linked. Publisher URLs move, and a citation that resolves to a 404 two years from now is worse than one you can search for by name — every entry below is findable from the title and year alone.